October 30, 2019 | Park Hyatt, Washington, DC
Resources and Background Materials
We have compiled background materials and helpful resources on some of the topics and policies that will be discussed during the 2019 Patient & Health Advocacy Summit for your reference. Please feel free to use these materials before, during, and after the event. We hope you find this information helpful!
BIO 2019 Patient and Health Advocacy Summit Session Slides
- International Reference Pricing and the Impact on Patient Access and Future Innovation
- Keynote: 2020 Election: Impact on Patient Access
- Wednesday Session Slides ALL
- Value Assessment Frameworks
- Thursday Session Slides ALL
Practices and Principles: Navigating the FDA
- CDER Patient-Focused Drug Development
- The Voice of the Patient: A Series of Reports from FDA's Patient-Focused Drug Development Initiative
- FDA Patient Affairs Staff
- FDA Patient Listening Sessions
- FDA-led Patient-Focused Drug Development (PFDD) Public Meetings
Closing the Gap: Partnering to Invest in Areas of Unmet Need
- The State of Innovation in Highly Prevalent Chronic Diseases:
- Volume I: Depression Therapeutics
- Volume II: Pain and Addiction Therapeutics
- Volume IV: Alzheimer’s Disease Therapeutics
- Volume III: Type 2 Diabetes and Obesity Therapeutics
2020 Election: Impact on Patient Access
International Reference Pricing and the Impact on Patient Access and Future Innovation
An Overview of Drug Pricing Proposals in Congress and the Administration
- BIO Issue Brief: International Reference Pricing
- BIO Issue Brief: Drug Importation
- BIO Infographic: The Partnership of Publicly Research & Private Innovation
- BIO Infographic: Biopharmaceutical Sector, A Driver of Innovation
- BIOtechNOW: The Challenges and Risks of Adopting Foreign Price Controls
- BIOtechNOW: Experts Weigh In on the Dangers of Importing Foreign Price Controls
- BIOtechNOW: Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innovation and Patient Access
- Pittsburgh Post-Gazette: Scientists can beat Alzheimer's
- STAT News: Pharma leaders: support the social contract on drug prices
- STAT News: Patients will be the losers as Pelosi’s plan to control drug prices nearly strikes out
- Boston Globe: Biopharmaceutical companies aren’t free-riding on government research
- Morning Consult: For Oncologists, Trump’s Medicare Part B Plan Makes Treating Cancer Harder
- STAT NEWS: Personalized treatments may be threatened by drug cost-containment proposals
- Bloomberg: House Drug Bill Would Save $345 Billion, Reshape Pharma Industry
- STAT News: CBO estimate on Pelosi drug bill misses its long-term impact on health
- USC Schaeffer Center White Paper: Global Burden of Medical Innovation
The Art of Storytelling
Value Assessment Frameworks
National Health Council Value Initiative Actions
Online series, currently comprised of seven modules, introduces the basics of health economics and value assessment. Each module takes between 10-15 minutes to complete.
- Patient-Driven Values in Healthcare Evaluation (PAVE) Center
- NHC Value Work Group
- NHC Report – Overcoming Barriers to Amplify Patient Voice
Principles for Interactions with Patient Advocacy Organization and Industry
- BIO Guiding Principles for Interaction with Patient Advocacy Organizations
- National Health Council Corporate Relations Standard
- National Health Council Standards of Excellence
- PhRMA Principles on Interactions with Patient Organizations
- International Alliance of Patients’ Organizations Consensus Framework for Ethical Collaboration between Patients’ Organizations, Healthcare Professionals and the Pharmaceutical Industry